Investigative Ophthalmology & Visual Science Cover Image for Volume 64, Issue 8
June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
OCT and OCTA complement glaucoma progression detection
Author Affiliations & Notes
  • Jo-Hsuan Wu
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Sasan Moghimi
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Takashi Nishida
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Golnoush Mahmoudinezhad
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Alireza Kamalipour
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Linda M Zangwill
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Robert Weinreb
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Jo-Hsuan Wu None; Sasan Moghimi National Eye Institute, UC Tobacco Related Disease Research Program, Code F (Financial Support); Takashi Nishida Topcon, Code C (Consultant/Contractor); Golnoush Mahmoudinezhad None; Alireza Kamalipour Fight for Sight, Code F (Financial Support); Linda Zangwill Abbvie, Topcon, Code C (Consultant/Contractor), National Eye Institute, Carl Zeiss Meditec Inc., Heidelberg Engineering GmbH, Optovue Inc., Topcon Medical Systems Inc., Code F (Financial Support), Carl Zeiss Meditec. AISight Health, Code P (Patent); Robert Weinreb Abbvie, Allergan, Amydis, Equinox, Eyenovia, Iantrek, IOPtic, Implandata, Nicox, Topcon, Code C (Consultant/Contractor), National Eye Institute, National Institute of Minority Health Disparities, Research to Prevent Blindness, Heidelberg Engineering, Carl Zeiss Meditec, Optovue, Centervue,Topcon, Code F (Financial Support), Toromedes, Carl Zeiss Meditec, Code P (Patent)
  • Footnotes
    Support  National Institutes of Health/National Eye Institute Grants (R01EY034148, R01EY029058, R01EY11008, R01EY19869, R01EY027510, R01EY026574, EY018926, P30EY022589); University of California Tobacco Related Disease Research Program (T31IP1511); unrestricted grant from Research to Prevent Blindness (New York, NY).
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2011. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jo-Hsuan Wu, Sasan Moghimi, Takashi Nishida, Golnoush Mahmoudinezhad, Alireza Kamalipour, Linda M Zangwill, Robert Weinreb; OCT and OCTA complement glaucoma progression detection. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2011.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To examine glaucoma progression detection by trend-based optical coherence tomography (OCT) and OCT angiography (OCTA) analysis.

Methods : Primary open-angle glaucoma (POAG) and glaucoma suspects eyes with at least 2-year and 4-visit of OCT/OCTA imaging were included. Peripapillary capillary density (CD) and retinal nerve fiber layer thickness (RNFL) were obtained from Angiovue 4.5x4.5mm2 optic nerve head scans. Progression was defined as a negative slope of OCT/OCTA change in linear regression with a P-value smaller than the 5th-percentile P-value derived from permutation analyses in a separate subset of healthy eyes. Visual field (VF) progression was assessed on VF mean deviation (MD) using the same method. Inter-instrument agreement on progression detection was compared using kappa(κ) statistics.

Results : From 147 eyes(96 subjects), OCTA and OCT identified 39(27%) and 36(24%) progressors, respectively. OCT and OCTA showed slight agreement (κ=0.16) for progression detection, with 14(10%) eyes categorized as progressors by both (Table 1). Similar results were observed in severity-stratified analyses (κ<0.20). Compared to progressors identified only by OCT, progressors identified only by OCTA had thinner baseline RNFL (71.8[65.7, 77.9] vs. 85.4[79.1, 91.7] µm), worse baseline VF (-5.6[-8.2, -2.9] vs. -2.2[-3.7, -0.8] dB), and thicker CCT (556[541, 570] vs. 526[503, 548] µm) (P<0.05). OCT progressors had faster VF (-0.36[-0.53, -0.19] vs. -0.16[-0.24, -0.09] dB/year; P<0.05) worsening than OCT non-progressors, with no difference in CD worsening rates. While OCTA progressors had faster VF (-0.39[-0.52, -0.25] vs. -0.15[-0.23, -0.07] dB/year; P<0.05) worsening than OCTA non-progressors, with no significant difference in RNFL worsening rates. VF progression was identified in 20(14%) eyes (Table 2). OCT and VF showed fair agreement (κ=0.22), with 10(7%) eyes categorized as progressors by both. OCTA and VF showed slight agreement (κ=0.11), with 8(5%) eyes categorized as progressors by both.

Conclusions : OCTA detected more progressors than OCT, and both detected more progressors than VF. OCT showed stronger agreement with VF than OCTA. Given the limited OCT/OCTA agreement, they may provide complementary information on glaucoma progression. Longer follow-up is needed to confirm the functional association of OCTA changes in glaucoma.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Agreement of OCT and OCTA on progression detection

Agreement of OCT and OCTA on progression detection

 

Agreement of VF with OCT and OCTA on progression detection

Agreement of VF with OCT and OCTA on progression detection

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×